Cosmetic use substances

​​​​​​​New laws apply to medicines from 5 November 2026​

From 5 November 2026 the Poisons and Therapeutic Goods Act and Regulation will be replaced by the:

This webpage outlines the requirements that will apply from 5 November 2026 onwards.​

​​​​​​ ​On this page​

​​​List of cosmetic use substances

Cosmetic use substances are Schedule 4 (prescription only) medicines that are used for cosmetic procedures and include: 

  • Botulinum toxins (commonly used as anti-wrinkle injections)
  • Dermal fillers and similar products, including:
    • calcium hydroxylapatite,
    • collagen,
    • hyaluronic acid and its polymers,
    • polyacrylamide,
    • polycaprolactone,
    • polylactic acid.​
  • Deoxycholic acid​

​Requirements for medical practitioners and nurse practitioners

A medical practitioner or nurse practitioner can only prescribe or give a direction for the administration of a cosmetic substance if the substance:

Before prescribing or giving a written direction for the use of these substances, the prescriber must ​personally review the patient in person or via video consultation.

A verbal direction is only allowed if the prescriber is physically present at the time of administration.

Written directions

Written directions are valid for 6 months and must be signed by the medical practitioner or nurse practitioner. The direction must include:

  • the ​patient details (name and address)
  • the prescriber details and contact information
  • the address where the substance will be administered
  • name of the responsible provider (clinic or business name)
  • the date of patient review
  • how long the direction applies for, and
  • how often the substance may be administered.

For each cosmetic use substance used for treatment the direction must include the following:

  • ​name and form of the substance
  • administration area of the face or body
  • route of administration (if not obvious)
  • quantity to be administered​.

​Record keeping

Medical practitioners and nurse practitioners must keep a record of all written or verbal directions.

  • Records of verbal directions must include the patient's street address.
  • A copy of these records must be provided to the responsible provider (business owners or operators).

[back to top]

Administration of cosmetic use substances

Cosmetic use substances may only be administered by the following authorised health practitioners:

  • Medical practitioners and nurse practitioners - as part of their lawful practice.
  • Nurses if they:
    • are acting in the course of their nursing practice, and
    • are directed by a medical practitioner or nurse practitioner to administer the substance, or
    • administer a cosmetic use substance that has been lawfully prescribed and dispensed for the patient.
  • In a hospital, administration may occur by a person acting under the direction of a medical or nurse practitioner.
  • For animals, administration is limited to veterinary practitioners or a person acting under their direction.

No other person is permitted to administer cosmetic use substances.

[back to top]

Responsibilities of nurses administering cosmetic use substances

A nurse administering a cosmetic use substance must:

  • ​ensure emergency equipment is available
  • confirm the substance to be administered is approved or lawfully supplied (ARTG listed, approved or supplied under the Therapeutic Goods Act as outlined above)
  • make a written record for each administration, and include the:
    • nurse’s name
    • date of administration
    • batch number of the substance administered
    • patient name and address
    • treatment details, including:
      • ​prescriber name, principal place of practice and telephone number,
      • address of premises that substance is being administered
      • name of the responsible provider
      • date that patient was reviewed by the prescriber
      • the period of time the direction for administration is valid for and the number of times and intervals between the administration
      • for each substance administered, the name, form, quantity and route (if not apparent) of administration, and the part the patient's face or body to which administration will occur

A copy of the administration ​record must be provided to:

  • ​the medical practitioner or nurse practitioner who gave the direction to administer the cosmetic use substance
  • the responsible provider of the business.

[back to top]

Storage requirements

​Cosmetic use substances must be stored:

  • in a non‑public area
  • separate from food
  • in a way that prevents contamination if containers break or leak
  • in line with the label’s storage instructions.

​These requirements apply both to clinics generally and to practitioners who obtain substances for administration.

[back to top]

​Responsibilities of cosmetic businesses

Busine​sses​ providing cosmetic procedures must ensure:

  • all cosmetic procedures comply with the legislation​
  • appropriate risk management policies and procedures are in place
  • appropriate emergency equipm​ent is available at all times
  • nurses who administer cosmetic substances are trained to respond to medical emergencies
  • prescriber directions and records of administration are made and kept​ for 2 years.

Record keeping

​Responsible providers (business owners and operators) must keep copies of all: 

  • ​written or verbal directions for administering a cosmetic use substance, as provided by medical practitioners or nurse practitioners
  • records of administration by nurses.​

[back to top]

New offences and increased penalties

The Act and Regulation outline penalties for offences​ associated with unauthorised activities.

Penalties are classified in 5 tiers​​​​ and differ for individuals and corporations. They range from 20 to 400 penalty units for individuals and 100 to 2000 penalty units for corporations.

More information is available in​ the Act and Regulation. Further information on compliance notices and penalties will be published at a later date. ​​ ​ ​​​​

More information

Supporting information to help understand the requirements of the legislation are available on the Pharmaceutical Services Medicines, Poisons and Therapeutic Goods legislation ​web​page.​

​Disclaimer​

The information on this webpage is provided for general guidance only. While reasonable care has been taken to ensure the accuracy, reliability, and currency of the information, users should refer to the Medicines, Poisons and Therapeutic Goods Act 2022 and the Medicines, Poisons and Therapeutic Goods Regulation 2026 for full and current legal requirements.

 

Current as at: Monday 6 July 2026
Contact page owner: Pharmaceutical Services